Bright Minds Biosciences to Present at Upcoming Conferences
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:
| EVENT: | 36th International Epilepsy Congress, Lisboa Congress Centre, Lisbon, Portugal |
| DATE: | August 30 – September 3, 2025 |
| EVENT: | Cantor Global Healthcare Conference 2025 |
| DATE: | Friday, September 5, 2025 |
| TIME: | 9:45am ET |
| WEBCAST: | https://stream.onstreammedia.com/onsm/GetReport?customerId=22&eventId=37737154 |
| EVENT: | H.C. Wainwright 27th Annual Global Investment Conference |
| DATE: | Tuesday, September 9, 2025 |
| TIME: | 3:00pm ET |
| WEBCAST: | There is no webcast for this event |
| EVENT: | Baird 2025 Global Healthcare Conference |
| DATE: | Wednesday, September 10, 2025 |
| TIME: | 9:05am ET |
| WEBCAST: | There is no webcast for this event |
The live and archived webcast for the Cantor event will be accessible from the Company’s website at https://brightmindsbio.com/investors/ under Events and Presentation. The replay of the webcast will be accessible for 60 days.
About Bright Minds Biosciences
Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.
Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
Contact Information
Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
